- Q3 2026 revenue grew 32% YoY to $1.025B, driven by metabolic condition therapies (+44%).
- GAAP net loss widened to -$123M (-$0.63/sh) vs -$31M (-$0.16/sh) YoY; Non-GAAP EPS came in at $0.23.
- Full-year 2026 Non-GAAP diluted EPS guidance slashed to $2.80–$3.10 (previously $4.90–$5.10); revenue outlook reduced.
?? Negative AI Sentiment (-6.5 / 10)